2010 Annual Meeting | Criteria for Stopping and Starting Multiple Sclerosis Therapy

Date Thursday 04/15/10

Time 06:45 AM - 08:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Breakfast Seminar

Director(s) Gary Birnbaum, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with some of the variables and difficulties involved in deciding when to start treatment with disease-modifying therapies in RRMS and when to stop such treatments in persons possibly no longer benefiting from them.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
06:30 AM - 08:30 AM		Breakfast
06:45 AM - 07:15 AM		When to Start Disease-modifying Therapy in MS Brian G. Weinshenker, MD, FAAN
07:15 AM - 07:45 AM		When to Stop Disease-modifying Therapy in MS Gary Birnbaum, MD, FAAN
07:45 AM - 08:00 AM		Break
08:00 AM - 08:30 AM		Questions and Answers

Faculty Disclosures
Gary Birnbaum, MD, FAAN	No disclosure on file
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. The institution of Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a speaker at internal meeting and symposium with Horizon.